Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a new study.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions that develop primarily as responses to drugs, and result in extensive epidermal detachment (upper layers of the skin detach from the lower layers). Recurrence has been reported in isolated cases, and the overall risk of recurrence has been unknown, according to background information in the article.
Yaron Finkelstein, M.D., of the Hospital for Sick Children, Toronto, and colleagues conducted a study that included data of all Ontario residents hospitalized for a first episode of Stevens-Johnson syndrome or toxic epidermal necrolysis between April 2002 and March 2011. Patients were followed up from admission until March 31, 2012, or death. The researchers identified 708 individuals hospitalized for a first episode of SJS (n = 567) or TEN (n = 141), including 127 (17.9 percent) children younger than 18 years.
Forty-two patients (7.2 percent) were hospitalized for a subsequent episode of Stevens-Johnson syndrome or toxic epidermal necrolysis. Eight patients (1.4 percent) experienced multiple recurrences. The median time to first recurrence was 315 days.
“In light of the reported incidence of SJS and TEN in the general population (1.0-7.2 cases/1 million individuals/year), the observed recurrence risk in our study (>7 percent) is several thousand-fold higher than would be expected if subsequent episodes were probabilistically independent of the first SJS or TEN episode. We speculate that this increased risk reflects individual susceptibility. Genetic predisposition has been identified for several medications in association with specific genotypes …” the authors write.
“… these findings are relevant to physicians who care for patients with a history of SJS or TEN. Because most such episodes are drug-induced, the high risk of recurrence should be recognized, and the benefits of drug therapy weighed carefully against the potential risks. This is particularly true for drugs commonly associated with the development of these frequently fatal conditions.”
Citation: Yaron Finkelstein MD, ABCP(Dip), Erin M. Macdonald MSc, Ping Li PhD, Janine R. Hutson MD, MSc, David N. Juurlink MD, PhD, 'Recurrence and Mortality Following Severe Cutaneous Adverse Reactions', JAMA. 2014;311(21):2231-2232. doi:10.1001/jama.2014.839
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Anti-Vaccine Beliefs Raced Around The World While Science Was Putting On Its Shoes
- James Hansen: To Mitigate Climate Change, Nuclear Energy Should Be Included
- Standards needed for post-conviction review of scientific evidence
- The Era Of The Atom
- Cardiovascular Risk Factors And Alzheimer's Disease Genetic Overlap
- Patrick Matthew, The Overlooked Third Man Of Natural Selection
- Can Moons Have Moonlets? Or Rings? Moonlets Of Pluto's Moons?
- "Co2, has little effect on incoming solar IR, wrong wavelengths. It does interact with out going..."
- "Beautiful, isn't it? There is a law universal in nature.... And of course human culture is as much..."
- "It should tell you all you need to know about vaccine safety when those who manufacture vaccines..."
- "I used to think the same. Internal Combustion Engines are part of a group known as Heat Engines..."
- "The linear range of an alpha particle is very small in materials, typically measured in microns..."